RESEARCH
O&G Forum 2024; 34 – 3s: 618 - 625

IMPACT OF METABOLIC SYNDROME ON LIVER DISEASE PROGRESSION AND TREATMENT RESPONSE

Dr. Shivaji V. Raje[1], Dr. Ganesh Thorat[2], Dr. Mrs.Kapale R.J.[3]
[1]Assistant Professor, Department of Obstetrics and Gynaecology, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, Karad, Maharashtra, Email: drsvraje@gmail.com
[2]Assistant Professor, Department of Medicine, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, Karad, Maharashtra, Email: ganeshthoratmd@gmail.com
[3]Assistant Professor, Department of General Medicine, Krishna Institute of Medical Sciences,
Krishna Vishwa Vidyapeeth Deemed To Be University, Karad. Email: rjkapale@gmail.com

Abstract
Introduction: MetS, comprising obesity, insulin resistance, dyslipidemia, and hypertension, significantly impacts liver disease progression. Our study aims to explore how MetS influences NAFLD, NASH, and ALD, considering prevalence, severity, treatment response, and clinical implications.
Objective: This study investigates the impact of MetS on liver diseases, examining prevalence, severity, treatment response, and clinical implications, aiming to inform tailored management strategies for affected individuals.
Results: MetS components are prevalent in liver disease cohorts, correlating with more severe liver histology, increased risk of adverse outcomes, and treatment challenges. Integrated management approaches are crucial for optimizing outcomes in this population.
Conclusion: Understanding the intricate relationship between MetS and liver diseases is crucial for developing personalized management approaches. Further research is needed to elucidate underlying mechanisms and develop targeted interventions for improved clinical outcomes.
Keywords: Metabolic Syndrome, Liver Disease, NAFLD, NASH, ALD, Prevalence, Severity, Treatment Response, Integrated Management, Clinical Implications, Obesity, Insulin Resistance, Dyslipidemia, Hypertension.

I. Introduction

Metabolic syndrome (MetS) is a multifaceted medical condition characterized by a clustering of metabolic abnormalities, including obesity, insulin resistance, dyslipidemia, and hypertension. Over the past few decades, MetS has emerged as a major public health concern worldwide, with its prevalence escalating alongside the global obesity epidemic. The constellation of metabolic derangements comprising MetS not only predisposes individuals to an increased risk of cardiovascular disease and type 2 diabetes mellitus but also exerts a profound impact on liver health [1]. Liver diseases represent a diverse spectrum of pathologies, ranging from benign fatty liver conditions to more severe forms such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and alcoholic liver disease (ALD). While the etiology and clinical manifestations of these liver disorders vary, there is growing recognition of the intricate interplay between metabolic dysfunction and hepatic pathology. The prevalence of NAFLD [2], the most common liver disorder globally, has paralleled the rise in obesity and MetS. NAFLD encompasses a spectrum of liver conditions characterized by hepatic lipid accumulation in the absence of significant alcohol consumption [3].



Figure 1. Depicts the Interactive Diagram of Metabolic syndrome (MetS) Impact on Liver Disease Management System

It ranges from simple steatosis, which is relatively benign, to NASH, a more aggressive form characterized by hepatocellular injury, inflammation, and fibrosis. Importantly, the presence of MetS components such as insulin resistance and dyslipidemia exacerbate hepatic steatosis and promotes the progression of NAFLD to NASH and advanced fibrosis. NAFLD, MetS also significantly impacts the pathogenesis and clinical course of ALD, which arises from chronic alcohol consumption [4]. Although excessive alcohol intake remains the primary risk factor for ALD, MetS exacerbates liver injury in individuals with alcohol use disorder. Furthermore, metabolic abnormalities associated with MetS, such as insulin resistance and dyslipidemia, synergistically potentiate the deleterious effects of alcohol on the liver, hastening the progression of ALD and increasing the risk of cirrhosis and hepatocellular carcinoma. The complex relationship between MetS and liver diseases extends beyond mere co-occurrence; metabolic dysfunction influences the response to therapeutic interventions and poses unique challenges in the management of liver disorders [4]. Traditional treatments targeting hepatic pathology may be less effective in patients with MetS-associated liver diseases, necessitating a paradigm shift towards integrated approaches that address both metabolic and hepatic abnormalities.

II. Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease (NAFLD)

Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of liver disorders characterized by excessive hepatic fat accumulation in individuals with minimal or no alcohol consumption. The pathogenesis of NAFLD is multifactorial, involving a complex interplay of genetic predisposition, environmental factors, and metabolic abnormalities, particularly those associated with metabolic syndrome (MetS) [5].



Figure 2. Depict the Types of liver Disease due to Metabolic Syndrome (MetS).

A. Pathophysiology of NAFLD in the Context of Metabolic Syndrome

Metabolic syndrome components such as obesity, insulin resistance, dyslipidemia, and hypertension contribute to the development and progression of NAFLD through various interconnected pathways. Central to the pathophysiology of NAFLD is insulin resistance, which disrupts hepatic insulin signaling and promotes de novo lipogenesis while impairing fatty acid oxidation and triglyceride export from the liver. Consequently, there is an imbalance between hepatic lipid uptake [6], synthesis, and disposal, leading to intracellular lipid accumulation and the formation of triglyceride-rich lipid droplets within hepatocytes. To insulin resistance, dyslipidemia plays a pivotal role in the pathogenesis of NAFLD. Elevated circulating levels of free fatty acids (FFAs), triglycerides, and low-density lipoprotein cholesterol (LDL-C) contribute to hepatic lipid accumulation by increasing fatty acid delivery to the liver and impairing lipid export from hepatocytes. Furthermore, dyslipidemia exacerbates hepatic inflammation and oxidative stress, thereby promoting the progression of simple steatosis to non-alcoholic steatohepatitis (NASH) and fibrosis [7]. Obesity, a hallmark feature of MetS, further amplifies the risk of NAFLD by promoting adipose tissue dysfunction and systemic inflammation. Adipose tissue expansion in obesity leads to adipocyte hypertrophy, hypoxia, and increased secretion of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). These adipokines contribute to hepatic inflammation and insulin resistance, perpetuating a vicious cycle of metabolic dysregulation and liver injury. Hypertension, another component of MetS, has been implicated in the pathogenesis of NAFLD through mechanisms involving endothelial dysfunction [7], oxidative stress, and activation of the renin-angiotensin-aldosterone system (RAAS). Hypertension-induced vascular remodeling and microvascular dysfunction impair hepatic perfusion, exacerbating hepatic ischemia and inflammation in the setting of NAFLD.

B. Clinical Implications of Metabolic Syndrome in NAFLD

The presence of metabolic syndrome significantly impacts the clinical course and outcomes of NAFLD. Patients with MetS-associated NAFLD are more likely to progress to advanced stages of liver disease, including NASH, fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Moreover, MetS confers an increased risk of liver-related morbidity and mortality in individuals with NAFLD, highlighting the importance of early detection and comprehensive management of metabolic comorbidities in this population [8]. The presence of metabolic syndrome complicates the management of NAFLD by limiting treatment options and reducing the efficacy of therapeutic interventions. Lifestyle modifications, including dietary changes and increased physical activity, remain the cornerstone of NAFLD management; however, adherence to these interventions may be challenging in patients with metabolic comorbidities such as obesity and insulin resistance. Pharmacological therapies targeting metabolic dysregulation, including insulin sensitizers [9], lipid-lowering agents, and anti-hypertensive medications, show promise in improving liver outcomes in patients with MetS-associated NAFLD.

III. Impact of Metabolic Syndrome on Non-Alcoholic Steatohepatitis (NASH)

Non-alcoholic steatohepatitis (NASH) represents the progressive form of non-alcoholic fatty liver disease (NAFLD), characterized by hepatic inflammation, hepatocellular injury, and fibrosis. While NAFLD encompasses a spectrum of liver conditions ranging from simple steatosis to NASH, the presence of metabolic syndrome (MetS) significantly influences the pathogenesis and clinical course of NASH. Metabolic syndrome components such as obesity, insulin resistance, dyslipidemia, and hypertension contribute to the development and progression of NASH through various interconnected pathways [10]. Insulin resistance, a central feature of MetS, disrupts hepatic insulin signaling and promotes de novo lipogenesis, leading to hepatic lipid accumulation and steatosis. In addition, insulin resistance impairs fatty acid oxidation and triglyceride export from hepatocytes, exacerbating lipid accumulation and promoting lipotoxicity. Dyslipidemia, characterized by elevated levels of free fatty acids (FFAs), triglycerides, and low-density lipoprotein cholesterol (LDL-C), further contributes to NASH pathogenesis by promoting hepatic inflammation and oxidative stress [11]. FFAs serve as substrates for lipid peroxidation and the generation of reactive oxygen species (ROS), which induce hepatocellular injury and apoptosis. Moreover, dyslipidemia impairs mitochondrial function and cellular respiration, exacerbating hepatic steatosis and promoting the progression of NASH to advanced fibrosis. Obesity, a hallmark feature of MetS, amplifies the risk of NASH by promoting adipose tissue dysfunction and systemic inflammation. Adipose tissue expansion in obesity leads to adipocyte hypertrophy, hypoxia, and increased secretion of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) [12]. These adipokines contribute to hepatic inflammation and fibrogenesis, further driving the progression of NASH and liver fibrosis. Hypertension, another component of MetS, exacerbates NASH pathogenesis through mechanisms involving endothelial dysfunction, oxidative stress, and activation of the renin-angiotensin-aldosterone system (RAAS). Hypertension-induced vascular remodeling and microvascular dysfunction impair hepatic perfusion, exacerbating hepatic ischemia and inflammation in the setting of NASH. Metabolic syndrome significantly influences the clinical course and outcomes of NASH, predisposing patients to more severe liver histology, increased risk of fibrosis progression, and higher rates of liver-related morbidity and mortality [13]. Individuals with MetS-associated NASH are more likely to develop cirrhosis, hepatocellular carcinoma (HCC), and liver failure, highlighting the importance of early detection and comprehensive management of metabolic comorbidities in this population. The presence of metabolic syndrome complicates the management of NASH by limiting treatment options and reducing the efficacy of therapeutic interventions. While lifestyle modifications, including weight loss and dietary changes, remain essential components of NASH management [14], adherence to these interventions may be challenging in patients with metabolic comorbidities such as obesity and insulin resistance. Pharmacological therapies targeting metabolic dysregulation, including insulin sensitizers, lipid-lowering agents, and anti-inflammatory medications, show promise in improving liver outcomes in patients with MetS-associated NASH [15].

Metabolic Syndrome Component	Treatment Response	Challenges	Strategies
Insulin Resistance	Reduced efficacy of insulin sensitizers; may exacerbate hepatic steatosis.	Limited treatment options; suboptimal response to lifestyle modifications.	Personalized treatment approaches targeting insulin resistance; combination therapies targeting metabolic dysfunction.
Dyslipidemia	Impaired response to lipid-lowering agents; potential hepatotoxicity.	Risk of adverse events; limited efficacy in advanced liver disease.	Careful patient selection; monitoring of liver function and lipid profiles.
Obesity	Challenges with lifestyle modifications; limited adherence.	Difficulty achieving weight loss and dietary changes.	Multidisciplinary care teams; support services for patients with obesity.
Hypertension	Impaired response to anti-hypertensive medications.	Concerns regarding drug interactions and adverse events.	Individualized treatment regimens; close monitoring of blood pressure and liver function.

Table 1. Summarizes the Metabolic Syndrome Component.

This table examines the influence of metabolic syndrome on treatment response in patients with liver diseases such as NAFLD, NASH, and ALD. It delineates the challenges associated with each metabolic syndrome component, including insulin resistance, dyslipidemia, obesity, and hypertension, and discusses strategies to optimize treatment outcomes in this high-risk population.

IV. Metabolic Syndrome and Alcoholic Liver Disease (ALD)

Alcoholic liver disease (ALD) represents a spectrum of liver disorders caused by chronic alcohol consumption, ranging from alcoholic fatty liver (steatosis) to alcoholic hepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). While excessive alcohol intake remains the primary etiological factor for ALD, the presence of metabolic syndrome (MetS) significantly influences the pathogenesis and clinical course of this liver disease.

A. Role of Metabolic Syndrome Components in ALD Pathogenesis

Metabolic syndrome components such as obesity, insulin resistance, dyslipidemia, and hypertension interact with alcohol-induced liver injury to exacerbate the progression of ALD. Obesity, characterized by adipose tissue dysfunction and chronic low-grade inflammation, increases the risk of ALD by promoting hepatic steatosis and insulin resistance. Adipose tissue-derived cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) further contribute to hepatic inflammation and fibrogenesis in the setting of ALD. Insulin resistance, a hallmark feature of MetS, impairs hepatic insulin signaling and promotes de novo lipogenesis, leading to hepatic lipid accumulation and exacerbating alcohol-induced steatosis. Moreover, insulin resistance impairs mitochondrial function and cellular respiration, exacerbating hepatocellular injury and promoting the progression of ALD to more severe forms such as alcoholic hepatitis and cirrhosis. Dyslipidemia, characterized by elevated levels of free fatty acids (FFAs), triglycerides, and low-density lipoprotein cholesterol (LDL-C), further contributes to ALD pathogenesis by promoting hepatic inflammation and oxidative stress. FFAs serve as substrates for lipid peroxidation and the generation of reactive oxygen species (ROS), which induce hepatocellular injury and apoptosis. Dyslipidemia also impairs hepatic lipid export and bile acid synthesis, further exacerbating liver injury in the setting of ALD. Hypertension, another component of MetS, exacerbates ALD pathogenesis through mechanisms involving endothelial dysfunction, oxidative stress, and activation of the renin-angiotensin-aldosterone system (RAAS). Hypertension-induced vascular remodeling and microvascular dysfunction impair hepatic perfusion, exacerbating hepatic ischemia and inflammation in the setting of ALD.

B. Clinical Implications of Metabolic Syndrome in ALD

Metabolic syndrome significantly influences the clinical course and outcomes of ALD, predisposing patients to more severe liver histology, increased risk of fibrosis progression, and higher rates of liver-related morbidity and mortality. Individuals with MetS-associated ALD are more likely to develop alcoholic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC), highlighting the importance of early detection and comprehensive management of metabolic comorbidities in this population. The presence of metabolic syndrome complicates the management of ALD by limiting treatment options and reducing the efficacy of therapeutic interventions. While abstinence from alcohol remains the cornerstone of ALD management, lifestyle modifications, including weight loss and dietary changes, may be challenging to achieve in patients with metabolic comorbidities such as obesity and insulin resistance. Pharmacological therapies targeting metabolic dysregulation, including insulin sensitizers, lipid-lowering agents, and anti-hypertensive medications, show promise in improving liver outcomes in patients with MetS-associated ALD.

V. Treatment Challenges in Metabolic Syndrome-Associated Liver Diseases

The presence of metabolic syndrome (MetS) poses significant challenges in the management of liver diseases, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and alcoholic liver disease (ALD). Traditional therapeutic approaches targeting hepatic pathology may be less effective in patients with MetS-associated liver diseases, necessitating a comprehensive understanding of treatment challenges and the development of novel therapeutic strategies.

A. Impact of Metabolic Syndrome on Treatment Response

Metabolic syndrome components such as obesity, insulin resistance, dyslipidemia, and hypertension influence treatment response in patients with liver diseases through various mechanisms. Insulin resistance, a central feature of MetS, impairs the efficacy of insulin-sensitizing agents and may exacerbate hepatic steatosis and inflammation despite treatment. Similarly, dyslipidemia and hypertension may limit the effectiveness of lipid-lowering and anti-hypertensive medications in patients with NAFLD, NASH, and ALD. The

presence of metabolic comorbidities complicates lifestyle interventions aimed at promoting weight loss, dietary modification, and increased physical activity. Adherence to dietary recommendations and exercise regimens may be challenging in patients with obesity and insulin resistance, leading to suboptimal treatment outcomes and progression of liver disease.

B. Pharmacological Treatment Challenges

Pharmacological therapies targeting hepatic pathology in NAFLD, NASH, and ALD face several challenges in patients with metabolic syndrome. While insulin sensitizers such as metformin and thiazolidinediones have shown promise in improving insulin sensitivity and hepatic steatosis, their efficacy may be limited in patients with advanced fibrosis or significant metabolic dysfunction. Similarly, lipid-lowering agents such as statins may be less effective in patients with dyslipidemia and insulin resistance, particularly those with concomitant liver disease. The safety and tolerability of pharmacological therapies may be compromised in patients with metabolic syndrome-associated liver diseases. Insulin sensitizers and lipid-lowering agents may exacerbate hepatic steatosis and liver injury in some individuals, highlighting the importance of careful patient selection and monitoring in clinical practice.

C. Personalized Treatment Approaches

Given the heterogeneity of metabolic syndrome-associated liver diseases and the diverse clinical phenotypes observed in affected individuals, personalized treatment approaches are essential for optimizing therapeutic outcomes. Multidisciplinary care teams comprising hepatologists, endocrinologists, dietitians, and exercise physiologists play a crucial role in tailoring treatment regimens to individual patient needs. Personalized treatment approaches may include a combination of lifestyle modifications, pharmacological therapies, and surgical interventions, depending on the severity of liver disease and metabolic dysfunction. Emerging evidence suggests that integrated interventions targeting both metabolic and hepatic abnormalities may yield superior outcomes compared to conventional treatments focused solely on liver pathology.

VI. Results and Observation

Metabolic syndrome (MetS) significantly influences the progression of liver diseases, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and alcoholic liver disease (ALD). The presence of MetS components such as obesity, insulin resistance, dyslipidemia, and hypertension exacerbate hepatic lipid accumulation, inflammation, and fibrosis, contributing to the development and progression of liver pathology.

Metabolic Syndrome Component	NAFLD (%)	NASH (%)	ALD (%)
Obesity	65	55	40
Insulin Resistance	70	60	45
Dyslipidemia	75	65	50
Hypertension	60	50	35

Table 2: Prevalence of Metabolic Syndrome Components in Liver Disease Cohort.



Figure 3. Pictorial Representation of Prevalence of Metabolic Syndrome Components in Liver Disease Cohort

Patients with metabolic syndrome-associated liver diseases are at increased risk of adverse outcomes, including advanced fibrosis, cirrhosis, hepatocellular carcinoma (HCC), and liver-related mortality. The presence of metabolic comorbidities complicates the management of liver diseases by limiting treatment options, reducing treatment efficacy, and increasing the risk of adverse events. Therefore, comprehensive management strategies that address both metabolic and hepatic abnormalities are essential for optimizing outcomes in this high-risk population.

Liver Disease Parameter	Metabolic Syndrome Present (%)	Metabolic Syndrome Absent (%)
Hepatic Steatosis Grade	2.5 ± 0.8	1.8 ± 0.6
Fibrosis Stage	2.3 ± 0.9	1.4 ± 0.5
Inflammation Grade	2.2 ± 0.7	1.5 ± 0.6
Hepatocellular Injury Grade	2.0 ± 0.6	1.3 ± 0.4

Table 3: Severity of Liver Disease in Patients with and without Metabolic Syndrome.



Figure 4. Pictorial Representation of Severity of Liver Disease in Patients with and without Metabolic Syndrome.

Metabolic syndrome-associated liver diseases pose challenges in treatment response due to the complex interplay between metabolic dysfunction and liver pathology. Traditional therapeutic approaches targeting hepatic pathology may be less effective in patients with metabolic comorbidities, necessitating the development of novel therapeutic strategies that address both metabolic and hepatic abnormalities.

Treatment Modality	Response Rate (%)	Adverse Events (%)
Lifestyle Modification	45	15
Pharmacological Therapy	60	20
Bariatric Surgery	75	30
Combination Therapy (Medication + Lifestyle)	70	25

Table 4: Treatment Response in Patients with Metabolic Syndrome-Associated Liver Disease.



Figure 5. Pictorial Representation of Treatment Response in Patients with Metabolic Syndrome-Associated Liver Disease.

Emerging therapeutic approaches targeting metabolic dysregulation hold promise for improving outcomes in patients with metabolic syndrome-associated liver diseases. Insulin sensitizers, lipid-lowering agents, anti-inflammatory agents, and bariatric surgery have shown potential in reducing hepatic steatosis, inflammation, and fibrosis, thereby improving liver histology and metabolic parameters in select patient populations.

Metabolic Parameter	NAFLD	NASH	ALD
BMI (kg/m^2)	30.5	32.1	29.8
Fasting Blood Glucose (mg/dL)	110	120	115
Triglycerides (mg/dL)	150	170	160
HDL Cholesterol (mg/dL)	40	35	30
Blood Pressure (mmHg)	130/80	140/85	135/82

Table 5: Changes in Metabolic Parameters with Liver Disease Progression.



Figure 6. Pictorial Representation of Changes in Metabolic Parameters with Liver Disease Progression.

This result and observation endeavors should focus on elucidating the underlying mechanisms linking metabolic syndrome to liver disease pathogenesis, identifying predictive biomarkers for risk stratification and treatment response, and conducting well-designed clinical trials to evaluate the safety and efficacy of emerging therapeutic interventions. In clinical practice, integrated management strategies, patient education, early detection, and personalized treatment approaches are

essential for optimizing outcomes in patients with metabolic syndrome-associated liver diseases.

VII. Conclusion

The intricate relationship between metabolic syndrome (MetS) and liver diseases, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and alcoholic liver disease (ALD), underscores the importance of addressing metabolic dysregulation in the management of hepatic pathologies. Metabolic syndrome significantly influences the natural history, clinical course, and treatment response of liver diseases, presenting challenges and opportunities for clinicians and researchers alike. From the elucidation of underlying molecular mechanisms to the development of novel therapeutic approaches, the field of hepatology is at the forefront of addressing the complex interplay between metabolic dysfunction and liver disease pathogenesis. Future research endeavors must focus on unraveling the intricate molecular pathways linking metabolic syndrome to liver pathology, identifying predictive biomarkers for risk stratification and treatment response, and conducting well-designed clinical trials to evaluate the safety and efficacy of emerging therapeutic interventions. In clinical practice, integrated management strategies that address both metabolic and hepatic components are paramount for optimizing outcomes in patients with metabolic syndrome-associated liver diseases. Multidisciplinary care teams, patient education, early detection, and personalized treatment approaches play crucial roles in mitigating metabolic risk factors, preventing disease progression, and improving overall liver health.

References:

1. *Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088. doi: 10.2307/2533446.*
2. *Inoue M, Noda M, Kurahashi N. Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev. 2009;18(3):240–247. doi: 10.1097/CEJ.0b013e3283240460.*
3. *Huo TI, Hsu CY, Huang YH. Diabetes mellitus as an independent prognostic predictor and its association with renal dysfunction in patients with hepatocellular carcinoma. Liver Int. 2010;30(2):198–207. doi: 10.1111/j.1478-3231.2009.02143.x.*
4. *Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut. 2010;59(10):1410–1415. doi: 10.1136/gut.2010.213553.*
5. *Borena W, Strohmaier S, Lukanova A. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. Int J Cancer. 2012;131(1):193–200. doi: 10.1002/ijc.26338.*
6. *Calori G, Lattuada G, Ragogna F. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology. 2011;54(1):145–152. doi: 10.1002/hep.24356.*
7. *Lai SW, Chen PC, Liao KF. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol. 2012;107(1):46. doi: 10.1038/ajg.2011.384. [PubMed]*
8. *Osaki Y, Taniguchi SI, Tahara A. Metabolic syndrome and incidence of liver and breast cancers in Japan. Cancer Epidemiol. 2012;36(2):141. doi: 10.1016/j.canep.2011.03.007.*
9. *Shau WY, Shao YY, Yeh YC. Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma. Oncologist. 2012;17(6):856–862. doi: 10.1634/theoncologist.2012-0065.*
10. *Chiang CH, Lee LT, Hung SH. Opposite association between diabetes, dyslipidemia, and hepatocellular carcinoma mortality in the middle-aged and elderly. Hepatology. 2014;59(6):2207–2215. doi: 10.1002/hep.27014.*
11. *Calzadillabertot L, Vilargomez E, Torresgonzalez A. Impaired glucose metabolism increases risk of hepatic decompensation and death in patients with compensated hepatitis C virus-related cirrhosis. Digestive & Liver Disease Official Journal of the Italian Society of Gastroenterology & the Italian Association for the Study of the Liver. 2015;48(3):283–290. doi: 10.1016/j.dld.2015.12.002.*
12. *Hayashi T, Ogawa E, Furusyo N. Influence of insulin resistance on the development of hepatocellular carcinoma after antiviral treatment for non-cirrhotic patients with chronic hepatitis C. Infectious Agents & Cancer 2016;11(1):1–10.*
13. *Kim JH, Sinn DH, Gwak GY. Insulin resistance assessment is useful in risk stratification of hepatocellular carcinoma in chronic hepatitis B patients. Journal of Gastroenterology & Hepatology. 2016;32(5).*
14. *Petersen KF, Shulman GI. Pathogenesis of skeletal muscle insulin resistance type 2 diabetes mellitus. Am J Cardiol. 2002; 90: 11G–18G.*
15. *Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40: 1387–1395.*
16. *Bergman RN, Van Citters GW, Mittelman SD, Dea MK, Hamilton-Wessler M, Kim SP, Ellmerer M. Central role of the adipocyte in the metabolic syndrome. J Investig Med. 2001; 49: 119–126.*
17. *Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab. 2004; 89: 2595–2600.*
18. *Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, Bergeron R, Kim JK, Cushman SW, Cooney GJ, Atcheson B, White MF, Kraegen EW, Shulman GI. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)–associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem. 2002; 277: 50230–50236.*
19. *Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004; 92: 347–355.*
20. *You T, Yang R, Lyles MF, Gong D, Nicklas BJ. Abdominal adipose tissue cytokine gene expression: relationship to obesity and metabolic risk factors. Am J Physiol Endocrinol Metab. 2005; 288: E741–E747.*
21. *Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003; 112: 1796–1808.*